Last reviewed · How we verify
HAIC of FOLFOX — Competitive Intelligence Brief
marketed
Chemotherapy combination (regional delivery)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
HAIC of FOLFOX (HAIC of FOLFOX) — Tianjin Medical University Cancer Institute and Hospital. HAIC (hepatic arterial infusion chemotherapy) of FOLFOX delivers chemotherapy directly into the hepatic artery to treat liver cancers with high local drug concentration.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HAIC of FOLFOX TARGET | HAIC of FOLFOX | Tianjin Medical University Cancer Institute and Hospital | marketed | Chemotherapy combination (regional delivery) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Chemotherapy combination (regional delivery) class)
- Tianjin Medical University Cancer Institute and Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HAIC of FOLFOX CI watch — RSS
- HAIC of FOLFOX CI watch — Atom
- HAIC of FOLFOX CI watch — JSON
- HAIC of FOLFOX alone — RSS
- Whole Chemotherapy combination (regional delivery) class — RSS
Cite this brief
Drug Landscape (2026). HAIC of FOLFOX — Competitive Intelligence Brief. https://druglandscape.com/ci/haic-of-folfox. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab